In this exciting webinar, our experts delve into antibody-drug conjugate (ADC) manufacturing and the recommended strategies to overcome common challenges in potency testing and product purity. ADCs are an advanced approach in the field of biomedicine that aims to target and treat various diseases in innovative ways, though there are often challenges which require innovative solutions for development, scale-up, and commercialization.
Particularly, when it comes to ADC manufacturing, two key challenges lie in the realms of potency testing and product purity. Furthermore, robust tools and streamlined processes are required to ensure the timely production of ADCs for clinical trials and commercial launches. Additionally, meeting regulatory standards adds another layer of complexity to the manufacturing process.
Thankfully, there are way to ensuring the highest quality outcomes for ADC projects. One such advantage lies in the utilization of cGMP grade materials, such as dehydroascorbic acid (DHAA) and tris(2-carboxyethyl phosphine) (TCEP) reagents. These high-quality materials are crucial in conjugation chemistry, facilitating efficient and precise antibody-drug conjugation.
Throughout this webinar, we’ll explore the challenges outlined above, examining their impact and potential solutions for advancing ADC manufacturing, share insights into the advantages of utilizing cGMP grade DHAA and TCEP in ADC manufacturing, and discuss the effective approaches for addressing potency testing and product purity challenges.
Jean-Francois Vincent-Rocan, Director of Complex Chemistry Process Development, BIOVECTRA
Jean-Francois Vincent-Rocan obtained his PhD in chemistry, specializing in heterocyclic compounds. As the Director of Process Development at BIOVECTRA, he leads a team of 15 scientists in designing and developing scalable processes for small molecule manufacturing.
Alex Hendry, Project Manager — Business Development & Marketing, BIOVECTRA
Alex Hendry, with a BSc in Medicinal Chemistry and an MBA, has been a valuable member of the BIOVECTRA team for 14 years. He has held various roles, including customer service, business development, and project management. As a product/market manager, Alex focuses on expanding the bioreagents business through portfolio growth and exploring new applications and markets.
Who Should Attend?
This webinar will appeal to mid/senior-level professionals from pharmaceutical and biotechnology companies and research/academic institutions in the following areas:
- Biochemistry and molecular biology
- Chemistry/professional chemistry/medicinal chemistry
- Analytical chemistry
- API manufacturing
- Chemical and biochemical engineering
- Manufacturing engineering
- Processes Safety Scientists
- Chief Scientific Officers
- Research Scientists
What You Will Learn
Attendees will gain insights into:
- Benefits of using cGMP grade DHAA and TCEP
- Strategies to overcome common challenges in potency testing and product purity
- Ways to identify the right team and support staff to assist with the success and completion of the project
BIOVECTRA is a global biotech and pharmaceutical CDMO that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients. Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, 550+ employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.